Mithun V Shah

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4961764/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Use of sublingual tacrolimus in adults undergoing hematopoietic cell transplant: A pilot study. Journal of Oncology Pharmacy Practice, 2022, 28, 387-394.	0.9	0
2	Genetic features and clinical outcomes of patients with isolated and comutated <i>DDX41</i> -mutated myeloid neoplasms. Blood Advances, 2022, 6, 528-532.	5.2	27
3	Sustained, complete response to pexidartinib in a patient with <scp><i>CSF1R</i></scp> â€mutated Erdheim–Chester disease. American Journal of Hematology, 2022, 97, 293-302.	4.1	9
4	Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience. Oncologist, 2022, 27, 144-148.	3.7	3
5	A <scp>populationâ€based</scp> study of acute panmyelosis with myelofibrosis in the United States: 2004–2015. American Journal of Hematology, 2022, 97, .	4.1	1
6	Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval. Leukemia Research, 2022, 112, 106770.	0.8	4
7	Midostaurin therapy for indolent and smoldering systemic mastocytosis: Retrospective review of Mayo Clinic experience. American Journal of Hematology, 2022, 97, .	4.1	7
8	<i>SF3B1</i> -mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity. Haematologica, 2022, 107, 1189-1192.	3.5	3
9	lsolated anemia in patients with large granular lymphocytic leukemia (LGLL). Blood Cancer Journal, 2022, 12, 30.	6.2	4
10	Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents. Blood Advances, 2022, 6, 5227-5231.	5.2	5
11	Realâ€world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts. American Journal of Hematology, 2022, 97, .	4.1	10
12	Factors Predicting Survival Following Allogeneic Stem Cell Transplant in Patients with Therapy-Related Myeloid Neoplasms. Transplantation and Cellular Therapy, 2022, 28, S137-S138.	1.2	2
13	Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3â€: Blood Cancer Journal, 2022, 12, 55.	6.2	4
14	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). Blood Cancer Journal, 2022, 12, 62.	6.2	6
15	Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning. Blood Advances, 2022, , .	5.2	1
16	Outcomes following venetoclaxâ€based treatment in therapyâ€related myeloid neoplasms. American Journal of Hematology, 2022, 97, 1013-1022.	4.1	7
17	Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A realâ€world experience. British Journal of Haematology, 2022, 198, .	2.5	7
18	Clinical features and outcomes of non-pulmonary unifocal adult Langerhans cell histiocytosis. Blood Cancer Journal, 2022, 12, .	6.2	3

#	Article	IF	CITATIONS
19	Characteristics and prognosis of mutated <i>STAG2</i> myeloid neoplasms Journal of Clinical Oncology, 2022, 40, e19014-e19014.	1.6	0
20	Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs. Blood Cancer Journal, 2022, 12, .	6.2	1
21	A dynamic 3â€ f actor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. American Journal of Hematology, 2022, 97, 1127-1134.	4.1	7
22	Phase II trial of luspatercept with or without hydroxyurea for the treatment of patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts Journal of Clinical Oncology, 2022, 40, TPS7080-TPS7080.	1.6	0
23	Characteristics and prognosis of <i>DDX41</i> - and <i>GATA2</i> -mutated myeloid neoplasms Journal of Clinical Oncology, 2022, 40, e19010-e19010.	1.6	0
24	Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis Journal of Clinical Oncology, 2022, 40, 8057-8057.	1.6	0
25	Clinical and therapeutic implications of BRAF fusions in histiocytic disorders. Blood Cancer Journal, 2022, 12, .	6.2	7
26	Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms. Blood Cancer Journal, 2022, 12, .	6.2	7
27	Risk of relapse in patients receiving azithromycin after allogeneic HSCT. Bone Marrow Transplantation, 2021, 56, 960-962.	2.4	3
28	PD-1/PD-L1 expression in extramedullary lesions of acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 764-767.	1.3	7
29	Singleâ€agent cladribine as an effective frontâ€line therapy for adults with Langerhans cell histiocytosis. American Journal of Hematology, 2021, 96, E146-E150.	4.1	21
30	Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. Blood Cancer Journal, 2021, 11, 49.	6.2	28
31	Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. Blood Cancer Journal, 2021, 11, 43.	6.2	11
32	Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. Blood Cancer Journal, 2021, 11, 47.	6.2	7
33	Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. Blood Cancer Journal, 2021, 11, 63.	6.2	11
34	Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. British Journal of Haematology, 2021, 193, 1004-1008.	2.5	8
35	Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. Blood Advances, 2021, 5, 2272-2278.	5.2	19
36	Outpatient practice pattern and remote patient monitoring for axicabtagene ciloleucel CAR-T therapy in patients with aggressive lymphoma. Journal of Clinical Oncology, 2021, 39, 7554-7554.	1.6	7

#	Article	IF	CITATIONS
37	A population-based study of acute panmyelosis with myelofibrosis in the United States: 2004 to 2015 Journal of Clinical Oncology, 2021, 39, e19003-e19003.	1.6	0
38	Phenotypes and prognostic factors in adults with Langerhans cell histiocytosis Journal of Clinical Oncology, 2021, 39, 7049-7049.	1.6	0
39	<i>BRAF</i> ^{V600E} frequency and impact on outcomes in adults with langerhans cell histiocytosis Journal of Clinical Oncology, 2021, 39, 7050-7050.	1.6	Ο
40	Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. Blood Cancer Journal, 2021, 11, 122.	6.2	7
41	Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival. American Journal of Hematology, 2021, 96, 1604-1610.	4.1	18
42	Single-Antibody Evaluation of T-Cell Receptor β Constant Chain Monotypia by Flow Cytometry Facilitates the Diagnosis of T-Cell Large Granular Lymphocytic Leukemia. American Journal of Clinical Pathology, 2021, 156, 139-148.	0.7	15
43	A populationâ€based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series. American Journal of Hematology, 2021, 96, E464-E468.	4.1	9
44	Improved Clinical Outcome of Patients with Myelodysplastic Syndrome (MDS) Progressing after Hypomethylating Agent: In the Era of Novel Therapies. Blood, 2021, 138, 3688-3688.	1.4	0
45	Outcome of Therapy-Related Myeloid Neoplasms with Venetoclax-Based Therapy. Blood, 2021, 138, 36-36.	1.4	0
46	Efficacy of Cobimetinib in Rosai-Dorfman Disease. Blood, 2021, 138, 1506-1506.	1.4	1
47	Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90. Blood, 2021, 138, 1267-1267.	1.4	Ο
48	Clonal Compositions Involving Epigenetic Regulator Gene Mutations in Clonal Hematopoiesis, Clonal Cytopenias of Undetermined Significance and Chronic Myelomonocytic Leukemia. Blood, 2021, 138, 2592-2592.	1.4	0
49	Cardiac Events in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents. Blood, 2021, 138, 219-219.	1.4	3
50	Differential Prognostic Impact of IDH1 and IDH2 Mutations in Chronic Myelomonocytic Leukemia. Blood, 2021, 138, 3684-3684.	1.4	0
51	Classical and Non-Classical Phenotypes of Erdheim-Chester Disease: Correlating Clinical, Radiographic, and Genotypic Findings. Blood, 2021, 138, 2566-2566.	1.4	0
52	Mimics of Erdheimâ \in "Chester disease. British Journal of Haematology, 2021, , .	2.5	3
53	A novel lowaâ \in Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction. Blood Cancer Journal, 2021, 11, 183.	6.2	0
54	Therapy-Related Cytopenia of Undetermined Significance (t-CCUS) As a Precursor to Therapy-Related Myeloid Neoplasms (t-MN). Blood, 2021, 138, 1096-1096.	1.4	0

#	Article	lF	CITATIONS
55	Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy. Blood, 2021, 138, 3368-3368.	1.4	1
56	Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience. Blood, 2021, 138, 3691-3691.	1.4	1
57	T-MDS Is a Distinct Clinical and Pathological Entity Characterized By Better Survival Compared to t-AML. Blood, 2021, 138, 3377-3377.	1.4	0
58	Hypomethylating Therapy Does Not Improve Outcome of Therapy-Related Myeloid Neoplasm Including TP53 Mutated and Complex Karyotype Subgroups. Blood, 2021, 138, 3702-3702.	1.4	3
59	Tumor Mutational Burden in Histiocytic Neoplasms. Blood, 2021, 138, 3634-3634.	1.4	0
60	Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy. Blood, 2021, 138, 568-568.	1.4	4
61	Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. Haematologica, 2020, 105, 348-357.	3.5	105
62	Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of <i>TET2</i> and <i>ZRSR2</i> mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving <i>CDK2NA/2NB</i> and <i>MTAP</i> . American Journal of Hematology, 2020, 95, E31-E34.	4.1	2
63	Clinical utility of fluorescence in situ hybridizationâ€based diagnosis of <i>BCRâ€ABL1</i> like (<scp>P</scp> hiladelphia chromosome like) <scp>B</scp> â€acute lymphoblastic leukemia. American Journal of Hematology, 2020, 95, E68-E72.	4.1	4
64	Efficacy of BRAF-Inhibitor Therapy in <i>BRAF V600E</i> -Mutated Adult Langerhans Cell Histiocytosis. Oncologist, 2020, 25, 1001-1004.	3.7	25
65	Low-dose vemurafenib monotherapy in <i>BRAF^{V600E}</i> -mutated Erdheim-Chester disease. Leukemia and Lymphoma, 2020, 61, 2733-2737.	1.3	9
66	Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. Blood Cancer Journal, 2020, 10, 121.	6.2	21
67	Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. American Journal of Hematology, 2020, 95, 1511-1521.	4.1	83
68	Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. Blood Advances, 2020, 4, 5425-5430.	5.2	16
69	A population-based study of chronic neutrophilic leukemia in the United States. Blood Cancer Journal, 2020, 10, 68.	6.2	8
70	Characteristics of patients with myelodysplastic syndrome with balanced translocations. British Journal of Haematology, 2020, 190, 244-248.	2.5	1
71	Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. Leukemia and Lymphoma, 2020, 61, 1592-1600.	1.3	17
72	Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a †̃graft versus host'-like syndrome and poor outcomes. Bone Marrow Transplantation, 2020, 55, 1879-1881.	2.4	1

#	Article	IF	CITATIONS
73	Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia. Genes, 2020, 11, 749.	2.4	30
74	A populationâ€based study of chronic eosinophilic <scp>leukemiaâ€not</scp> otherwise specified in the United States. American Journal of Hematology, 2020, 95, E257.	4.1	6
75	Characteristics of late transplantâ€associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2020, 95, 1170-1179.	4.1	19
76	Bone marrow findings in Erdheim-Chester disease: increased prevalence of chronic myeloid neoplasms. Haematologica, 2020, 105, e84-e86.	3.5	12
77	Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system. Annals of Hematology, 2020, 99, 513-518.	1.8	1
78	The differential diagnosis of basophilia in patients undergoing <scp>BCRâ€ABL</scp> testing. American Journal of Hematology, 2020, 95, E216-E217.	4.1	6
79	Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia. Blood, 2020, 136, 39-40.	1.4	1
80	Risk of Mortality and Leukemic Transformation in Primary Myelofibrosis before and after Ruxolitinib Approval. Blood, 2020, 136, 28-28.	1.4	2
81	A Population-Based Study of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis in the United States from 2001-2015. Blood, 2020, 136, 48-48.	1.4	0
82	The Role of Staging Evaluation at Initial Diagnosis of Adult Patients with Clinically Isolated Pulmonary Langerhans Cell Histiocytosis. Blood, 2020, 136, 45-45.	1.4	0
83	Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias. Blood, 2020, 136, 26-27.	1.4	1
84	Treatment Outcome for Symptomatic Patients with Clonal Cytopenia of Undetermined Significance: A Single-Institution Retrospective Study. Blood, 2020, 136, 44-44.	1.4	0
85	Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. Blood, 2020, 136, 35-36.	1.4	0
86	A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015. Blood, 2020, 136, 30-31.	1.4	0
87	Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 26-27.	1.4	1
88	Pre- Transplant Ferritin Predicts Overall Survival and Non-Relapse Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis. Blood, 2020, 136, 19-20.	1.4	0
89	The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease. Mayo Clinic Proceedings, 2019, 94, 2054-2071.	3.0	116
90	Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms. Blood, 2019, 133, 1607-1610.	1.4	23

#	Article	IF	CITATIONS
91	Extranodal Rosai-Dorfman Disease Presenting as a Pericardial Mass and Constrictive Pericarditis. JACC: Case Reports, 2019, 1, 643-647.	0.6	Ο
92	Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. Leukemia and Lymphoma, 2019, 60, 990-999.	1.3	9
93	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Flurabine Improves Transplant Outcomes in Older MDS Patients. Blood, 2019, 134, 253-253.	1.4	1
94	Single-Agent Cladribine As an Effective Therapy for Adults with Langerhans Cell Histiocytosis. Blood, 2019, 134, 4189-4189.	1.4	2
95	Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation. Blood, 2019, 134, 4560-4560.	1.4	1
96	Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma. Blood, 2019, 134, 4106-4106.	1.4	6
97	Clinical Features and Outcomes of Unifocal Adult Langerhans Cell Histiocytosis. Blood, 2019, 134, 1667-1667.	1.4	2
98	Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB). Blood, 2019, 134, 5441-5441.	1.4	0
99	Molecular Alterations in Adult Histiocytic Neoplasms. Blood, 2019, 134, 2975-2975.	1.4	2
100	Correlation of Flow Cytometric Aberrations with Cytogenetic, Molecular Genetic, and Morphology in Patients with Unexplained Cytopenias. Blood, 2019, 134, 5406-5406.	1.4	0
101	Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial. Blood, 2019, 134, 3863-3863.	1.4	1
102	Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes. Blood, 2019, 134, 3300-3300.	1.4	0
103	Desideromastica: Tactile Chew Cravings in Iron Deficiency Anemia. Blood, 2019, 134, 4815-4815.	1.4	Ο
104	Low-Dose BRAF-Inhibitors in the Treatment of Histiocytic Disorders with the BRAF-V600E Mutation. Blood, 2019, 134, 5895-5895.	1.4	2
105	Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and longâ€ŧerm outcomes. British Journal of Haematology, 2018, 182, 579-581.	2.5	43
106	Efficacy of biological agents in the treatment of Erdheim hester disease. British Journal of Haematology, 2018, 183, 520-524.	2.5	24
107	Arterial involvement in Erdheim–Chester disease. Medicine (United States), 2018, 97, e13452.	1.0	24
108	The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. American Journal of Hematology, 2018, 93, E355-E357.	4.1	2

#	Article	IF	CITATIONS
109	Marrow Blast Percentage Impact on High-Grade Myelodysplastic Syndrome By the Revised International Prognostic Scoring System. Blood, 2018, 132, 5510-5510.	1.4	0
110	The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia. Blood, 2018, 132, 5440-5440.	1.4	1
111	Tumor Mutational Burden and Other Immunotherapy Markers in Histiocytic Neoplasms Using Next Generation Sequencing. Blood, 2018, 132, 1112-1112.	1.4	1
112	Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease. JAMA Oncology, 2017, 3, 1253.	7.1	47
113	Clinical and radiological responses to oral methotrexate alone or in combination with other agents in Erdheim-Chester disease. Blood Cancer Journal, 2017, 7, 647.	6.2	8
114	Bilateral Foot Gangrene. JAMA Oncology, 2016, 2, 387.	7.1	2
115	Emerging role of <i>CEBP</i> â€Î± mutations in acute myeloid leukemia. European Journal of Haematology, 2015, 95, 99-100.	2.2	0
116	Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia. Science Translational Medicine, 2015, 7, 293ra102.	12.4	43
117	Erdheim-Chester Disease. Mayo Clinic Proceedings, 2015, 90, 1310.	3.0	5
118	Analysis of Serum Ferritin Levels As a Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis (HLH) in Hospitalized Adult Patients. Blood, 2015, 126, 1014-1014.	1.4	3
119	A Population-Based Study of Large Granular Lymphocyte Leukemia: Analysis of 978 Patients Using the SEER and NCDB Databases. Blood, 2015, 126, 3302-3302.	1.4	0
120	MTH1 Inhibitor-Induced Cytotoxicity in Acute Myeloid Leukemia. Blood, 2015, 126, 1273-1273.	1.4	8
121	The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders. Hematological Oncology, 2010, 28, 105-117.	1.7	71